Aimmune Therapeutics
AIMT
AIMT was delisted on the 12th of October, 2020.
188 hedge funds and large institutions have $1.49B invested in Aimmune Therapeutics in 2020 Q3 according to their latest regulatory filings, with 85 funds opening new positions, 29 increasing their positions, 53 reducing their positions, and 60 closing their positions.
800% more funds holding in top 10
Funds holding in top 10: 1 → 9 (+8)
80% more capital invested
Capital invested by funds: $824M → $1.49B (+$662M)
42% more first-time investments, than exits
New positions opened: 85 | Existing positions closed: 60
14% more funds holding
Funds holding: 165 → 188 (+23)
14% less call options, than puts
Call options by funds: $33.2M | Put options by funds: $38.7M
45% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 53
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$53.3M |
| 2 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$44.2M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$41M |
| 4 |
Goldman Sachs
New York
|
+$40.2M |
| 5 |
GF
Gabelli Funds
Rye,
New York
|
+$24.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$88.1M |
| 2 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$70.2M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$53.4M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$49.1M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$44M |
AIMT Hedge Fund Activity: Q3 2020 in Review
188 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q3 2020, worth a combined $1.49B — up 80% from $824M a quarter earlier.
Buyers outnumbered sellers: 85 funds opened new AIMT positions and 60 closed out — a net gain of 25 holders — while 29 added to existing stakes and 53 trimmed.
The largest buyer was Pentwater Capital Management, opening a new position worth an estimated $53.3M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $88.1M sold.
- 188 institutional investors held Aimmune Therapeutics (AIMT) as of Q3 2020, up from 165 in Q2 2020.
- Funds reported $1.49B of Aimmune Therapeutics stock for Q3 2020, up 80% quarter-over-quarter.
- 85 funds opened new Aimmune Therapeutics positions in Q3 2020 and 60 closed out, a net change of +25 holders.
- The largest Aimmune Therapeutics buyer in Q3 2020 was Pentwater Capital Management, an estimated $53.3M added.
- The largest Aimmune Therapeutics seller in Q3 2020 was T. Rowe Price Associates, an estimated $88.1M sold.
Based on aggregated 13F filings for Q3 2020.